Xbrane Biopharma AB (SE:XBRANE)
:XBRANE
Want to see SE:XBRANE full AI Analyst Report?
Top Page
Xbrane Biopharma AB
(XBRANE)
Select Model
Select Model
Rating:49Neutral
Price Target:
kr11.00
▲(6.08% Upside)
Action:ReiteratedDate:05/01/26
The score is held back primarily by persistent operating losses and heavy ongoing cash burn despite a notably strengthened 2025 balance sheet. Technical indicators show improving short-term momentum, but the longer-term trend remains weak and valuation is constrained by negative earnings and no dividend support.
Positive Factors
Balance sheet strengthening
A materially stronger 2025 balance sheet meaningfully reduces leverage and refinancing risk, extending runway for R&D and partnering discussions. This durable capital base improves strategic optionality for clinical programs and deal-making over the next several quarters.
Negative Factors
Persistent cash burn
Consistent, deep negative operating and free cash flow forces ongoing external financing or dilutive capital raises. That structural cash burn constrains reinvestment, increases dilution risk, and limits the firm's ability to independently fund late-stage development or commercial scale-up.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strengthening
A materially stronger 2025 balance sheet meaningfully reduces leverage and refinancing risk, extending runway for R&D and partnering discussions. This durable capital base improves strategic optionality for clinical programs and deal-making over the next several quarters.
Read all positive factors
Xbrane Biopharma AB (XBRANE) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr226.66M
Dividend YieldN/A
Average Volume (3M)117.17K
Price to Earnings (P/E)―
Beta (1Y)1.21
Revenue Growth-23.33%
EPS GrowthN/A
CountrySE
Employees65
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.28
Shares Outstanding20,605,349
10 Day Avg. Volume189,097
30 Day Avg. Volume117,165
Financial Highlights & Ratios
PEG Ratio-1.22
Price to Book (P/B)27.69
Price to Sales (P/S)101.88
P/FCF Ratio-61.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-4.14
Revenue Forecast (FY)kr186.50M
Xbrane Biopharma AB Business Overview & Revenue Model
Company Description
Xbrane Biopharma AB (publ), a biotechnology company, develops, manufactures, and sells biosimilars. The company is developing Xlucane, a ranibizumab biosimilar that is in Phase III clinical trials used for the treatment of wet age-related macular ...
How the Company Makes Money
Xbrane primarily makes money through a combination of (1) out-licensing/partnering its biosimilar programs and (2) service-related income tied to biologics development and manufacturing work.
1) Partnering and licensing revenue: For biosimilar ca...
Xbrane Biopharma AB Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
62
Positive
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 152.35M | 198.70M | 238.73M | 57.62M | 11.53M |
| Gross Profit | 74.94M | 180.47M | 35.39M | 41.04M | -684.00K |
| EBITDA | -16.50M | -181.97M | -282.03M | -149.34M | -167.59M |
| Net Income | 127.24M | -266.22M | -388.17M | -172.23M | -191.01M |
Balance Sheet | |||||
| Total Assets | 671.62M | 842.43M | 653.51M | 690.51M | 688.43M |
| Cash, Cash Equivalents and Short-Term Investments | 86.59M | 124.33M | 65.40M | 193.99M | 295.18M |
| Total Debt | 58.31M | 191.72M | 231.48M | 38.22M | 44.38M |
| Total Liabilities | 110.97M | 633.89M | 482.17M | 265.63M | 256.69M |
| Stockholders Equity | 560.65M | 208.54M | 171.34M | 424.89M | 431.74M |
Cash Flow | |||||
| Free Cash Flow | -250.69M | -185.97M | -423.45M | -254.04M | -296.96M |
| Operating Cash Flow | -250.69M | -133.73M | -406.68M | -193.92M | -219.61M |
| Investing Cash Flow | -37.14M | -52.25M | -16.77M | -60.13M | -77.35M |
| Financing Cash Flow | 255.60M | 243.62M | 298.70M | 148.86M | 349.37M |
Xbrane Biopharma AB Technical Analysis
Positive
10.37
Price Trends
7.43
Positive
8.96
Positive
18.60
Negative
Market Momentum
0.62
Negative
86.38
Negative
92.04
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:XBRANE, the sentiment is Positive. The current price of 10.37 is above the 20-day moving average (MA) of 7.03, above the 50-day MA of 7.43, and below the 200-day MA of 18.60, indicating a neutral trend. The MACD of 0.62 indicates Negative momentum. The RSI at 86.38 is Negative, neither overbought nor oversold. The STOCH value of 92.04 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:XBRANE.
Xbrane Biopharma AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | kr389.21M | -3.40 | -25.80% | ― | 70.42% | 67.58% | |
52 Neutral | kr159.75M | -1.70 | -1291.15% | ― | ― | 44.58% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | kr226.66M | -44.78 | -16.90% | ― | -23.33% | ― | |
45 Neutral | kr314.13M | -1.89 | -16.51% | ― | ― | 18.65% | |
44 Neutral | kr380.61M | -4.79 | -79.60% | ― | ― | 48.34% | |
42 Neutral | kr21.38M | -0.24 | -186.13% | ― | ― | 19.98% |
* Healthcare Sector Average
SE:XBRANE
Xbrane Biopharma AB
11.00
-13.38
-54.87%
SE:ACE
Ascelia Pharma AB
3.00
-0.26
-7.98%
SE:IVACC
Intervacc AB
1.14
0.11
10.66%
SE:GUARD
Guard Therapeutics International AB
1.06
-12.44
-92.15%
SE:ACTI
Active Biotech AB
0.06
>-0.01
-6.25%
SE:IMMU
Immunicum AB
5.13
0.08
1.58%
Xbrane Biopharma AB Corporate Events
Xbrane Resubmits Ranibizumab Biosimilar Application to U.S. FDA
Apr 30, 2026
Xbrane Biopharma has resubmitted its Biologics License Application to the U.S. Food and Drug Administration for a ranibizumab biosimilar to Lucentis, targeting eye diseases such as age-related macular degeneration, retinal vein occlusion and myopi...
Xbrane Sets April–May Target to Resubmit Ranibizumab Biosimilar BLA to U.S. FDA
Mar 31, 2026
Xbrane Biopharma plans to resubmit its Biologics License Application for its ranibizumab biosimilar to the U.S. Food and Drug Administration in April or May 2026, following additional feedback related to a previous Complete Response Letter focused...
Xbrane Details Proxy Voting Procedure for 2026 Annual General Meeting
Mar 31, 2026
Xbrane Biopharma AB has outlined the procedure for shareholders to appoint a proxy to represent and vote their shares at the annual general meeting scheduled for 5 May 2026. Shareholders must complete and sign a proxy form, with additional documen...
Xbrane Swings to Profit as Ximluci Grows and Biosimilar Pipeline Advances
Feb 20, 2026
Xbrane Biopharma reported full-year 2025 revenue of SEK 152.4 million, with higher Ximluci product sales and license income contributing to a swing to a SEK 127.2 million profit from a large loss a year earlier, mainly driven by a gain from its Al...
Xbrane Biopharma Sets February 20 Teleconference to Present 2025 Year-End Results
Feb 13, 2026
Xbrane Biopharma AB has scheduled a teleconference and webcast for investors, analysts and media on February 20, 2026, at 09:00 CET, to present its 2025 year-end report, which will be published an hour earlier that same morning. Chief executive Ma...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.